Viking Therap

VKTX

----

Current ValuationThe current P/E ratio is -6.18, above the reasonable range, cheaper than 0.13% of the time in the past 3 years, and the industry ranks 402/604, the industry Median -2.09.

-6.18xP/E

Stock price$28.34Earnings per share$-4.58

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

020406080

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GILDUSGilead Sciences	-57.57x	148.62%	$186.53B
MRNAUSModerna	-27.08x	15.53%	$85.33B
CSLLYUSCSL Limited	-23.93x	--	$61.70B
NTRAUSNatera	-298.09x	6.99%	$57.34B
RVMDUSRevolution Medicines	-23.51x	62.12%	$41.57B
ROIVUSRoivant Sciences	-93.84x	146.49%	$24.99B
BNTXUSBioNTech SE	-12.32x	19.07%	$24.08B
INSMUSInsmed	-24.59x	74.54%	$21.52B
SMMTUSSummit Therapeutics	-15.96x	20.52%	$13.67B
BBIOUSBridgebio Pharma	-18.58x	29.04%	$12.85B
PCVXUSVaxcyte	-10.45x	48.18%	$11.12B
MDGLUSMadrigal Pharma	-33.20x	51.06%	$10.79B
IBRXUSImmunityBio	-10.81x	151.32%	$10.73B
TWSTUSTwist Bioscience	-73.12x	28.71%	$10.00B
KYMRUSKymera Therapeutics	-31.11x	5.24%	$9.32B
CYTKUSCytokinetics	-9.76x	6.46%	$8.73B
ARWRUSArrowHead Pharma	-26.81x	36,308.30%	$8.58B
ABVXUSAbivax SA	-16.30x	22.49%	$7.58B
SYREUSSpyre Therapeutics	-50.42x	45.67%	$7.57B
IONSUSIonis Pharma	-12.84x	50.60%	$7.26B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.